SVB Wealth LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,819 shares of the company’s stock, valued at approximately $556,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in AstraZeneca in the fourth quarter valued at $34,000. Fairscale Capital LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $37,000. Bell Investment Advisors Inc purchased a new position in AstraZeneca during the 1st quarter valued at about $39,000. Mascoma Wealth Management LLC acquired a new position in AstraZeneca during the fourth quarter worth about $46,000. Finally, Aventus Investment Advisors Inc. purchased a new stake in shares of AstraZeneca in the first quarter valued at about $46,000. 40.87% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Stock Performance
AZNCF stock opened at $187.10 on Thursday. The company’s 50 day simple moving average is $187.10 and its 200-day simple moving average is $186.19. AstraZeneca PLC has a 12 month low of $122.26 and a 12 month high of $195.00.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
